我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

The Antimicrobial Therapy of the Future: Combating Resistances

Beatriz Suay-García and María Teresa Pérez-Gracia*

The appearance of antibiotic resistance is an increasing problem in our society, where the adaptation of microorganisms to conventional therapies has been favored due to their incorrect use. This has driven the scientific community to develop new therapeutic alternatives hoping to obtain treatments that are more effective against increasingly resistant bacteria. The purpose of this study is to review the existent knowledge on the therapeutic alternatives that are being developed to treat cases of infection with antibiotic resistant bacteria. To do so, scientific publications were consulted on the MEDLINE database using different search terms. The bibliography consulted indicates that a great variety of therapeutic alternatives are currently being developed among which the most relevant are probiotics, synthetic peptides, bacteriophages and nanoparticles. Some of these measures, such as probiotics, are already being introduced in some hospitals with positive results. Others, such as synthetic peptides, bacteriophages or nanoparticles are still in the early stages of development and clinical trials. Moreover, there is a clear tendency to go back to the more classical medicine turning to plant extracts and essential oils whose active ingredients have been proven to have therapeutic activity. This shift towards less conventional therapies is marking the beginning of a post-antibacterial era in which antibiotics will most probably be replaced for probiotics, bacteriophages, synthetic peptides or even inorganic nanoparticles.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。